Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the Company’s announcement that it had received an R&D tax incentive refund of $2.75m.
Botanix Executive Director, Matt Callahan, visited Melbourne last week and took the time to participate in a boardroom interview with veteran business and biotech journalist, @Tim Boreham.
As part of this conversation, Matt Callahan explains the strategic importance of following the US Food and Drug Administration’s (FDA) clinical development blueprint, as we develop our dermatology and antimicrobial products, and reiterates the value of recruiting a highly experienced team at the helm.
He also explains the meticulous methodology underpinning Botanix’s clinical trial process and how we are moving our late-stage products even closer to large underserved patient cohorts in the world’s largest healthcare markets.
Take a look:
Botanix has today announced the appointment of a new Australian-based Non-Executive Director to the Board, Danny Sharp.
Danny is a highly respected investment banker with more than 30 years’ experience and strong networks within global capital markets, institutional investment and private wealth too. Healthcare and technology are his speciality areas of expertise.
Most recently, Danny was Corporate Finance Executive Director of Canaccord Genuity, and he has previously spearheaded the Corporate Finance departments at both Shaw and Partners and Lodge Partners.
Interested to learn more about the opportunities we are pursuing at Botanix, directly from the people at the centre of our clinical development work?
Over the next two months we’ll be sharing with you a Conversation Series, showcasing video interviews with specialist consultants and key opinion leaders who we are proud to have recruited to our leadership team.
The first of these is with Dr Ira Lawrence, a Medical Advisor with more than 30 years of senior leadership experience within the global pharmaceutical and medical device industries.
Watch this short video to hear what Dr Lawrence has to say about the future of dermatology.
Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly update.
Analyst Seth Lizee commented:
“The company is looking to shake up big markets in dermatology and antimicrobials with its four clinical programs. The prize, should individual programs ultimately be clinically successful, is huge.”
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly report.
2022 is described as “a big year ahead”.
A recent analysis published in The Lancet has highlighted the need for urgent action to address antibiotic-resistant bacterial infections.
New data has revealed that more than 1.2 million people – and potentially millions more – died in 2019 as a direct result of antibiotic-resistant bacterial infections.
According to the paper’s co-author Prof Chris Murray:
“These new data reveal the true scale of antimicrobial resistance worldwide, and are a clear signal that we must act now to combat the threat.”
Twelve months ago, Botanix published important research data in collaboration with the University of Queensland showing the ability of synthetic CBD to kill a select group of Gram-negative bacteria, and highlighting the potential of CBD as the foundation of a new class of antimicrobials.
Botanix (ASX $BOT) Executive Director, Matt Callahan, spoke with BBC journalist, Vivienne Parry, at the 2022 Edison Open House: Global Healthcare virtual event this week.
He detailed how the Company is harnessing valuable commercial opportunities in its dermatology and antimicrobial programs:
“This is a great time to be in dermatology. There’s a real dearth of innovation, and that innovation generally comes from small to medium companies. So we’re aiming to broaden our platform to really provide an M and A target for those larger companies as we move into the next 18 to 24 months.”
Botanix is one of only 34 companies selected to participate in the 2022 Edison Open House: Global Healthcare virtual event to be hosted by the Edison Group next week.
Join Botanix’s Executive Director, Matt Callahan, and science journalist, Vivienne Parry, at 7pm AEST on Tuesday 25th January 2022, as they discuss the upcoming developments for our dermatology and antimicrobial programs.
Click here to register, it’s free.
Last week, the Edison Group also published a quickview analyst report on Botanix Pharmaceuticals, an interesting snapshot of what’s to come for the Company in 2022.
Botanix Pharmaceuticals (ASX:BOT) is today hosting its Annual General Meeting (AGM) at 9:00am AWST at the offices of BDO, 38 Station Street, Subiaco, WA.
To coincide with this event, the Company has shared an updated corporate presentation, which consolidates its progress in the past financial year and the valuable opportunities Botanix is pursuing in dermatology and infection control.
